bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules | BIAF Stock News
bioAffinity Technologies, Inc. Q2 2026: Revenue $1.51M, EPS $(0.64) — 10-Q Summary
BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 8-K: FY2026 Q2 Revenue: USD 1.511 M
bioAffinity Q2 FY26 net loss narrows to $3.4 million; revenue rises 19% to $1.5 million
bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung | BIAF Stock News
bioAffinity Technologies Faces Nasdaq Delisting Risk After Notice